These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
While developed for type 2 diabetes, Retratrutide is widely studied off-label in non-diabetic individuals for research into obesity and metabolic health
Miguens-Gomez et al 2021)
doi: 10.1126/science.abe9985
Ya hemos nombrado Mounjaro, Ozempic, Wegovy, tambin est Saxenda, el primer medicamento que conocimos de este estilo